GlassScriptPhysician profile
Weiguo Li
NPI 1972640142
$24,239.33
in general payments reported to CMS, 2019-2025
44 companies · $5,199 in 2025
The $5,199 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,645 · 2020: $931 · 2021: $3,493 · 2022: $2,878 · 2023: $3,520 · 2024: $4,574 · 2025: $5,199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Travel and Lodging: $20.50 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,263.70 |
| Travel and Lodging | $20.50 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,212.97 | 2019-2025 | Farxiga, Fasenra, Tezspire |
| Abbvie INC. | $2,897.57 | 2019-2025 | |
| Esperion Therapeutics, INC. | $1,478.42 | 2020-2025 | Nexletol, Nexlizet |
| Gilead Sciences, INC. | $1,293.78 | 2021-2025 | Livdelzi, Vemlidy |
| Lilly USA, LLC | $1,149.31 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Merck Sharp & Dohme LLC | $1,129.67 | 2019-2025 | Verquvo, Belsomra, Januvia |
| Amgen INC. | $1,105.33 | 2019-2025 | Evenity, Krystexxa |
| Regeneron Healthcare Solutions, INC. | $1,056.63 | 2019-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $964.69 | 2020-2025 | Jardiance |
| Genzyme Corporation | $687.53 | 2024-2025 | |
| Nestle Healthcare Nutrition INC. | $547.54 | 2021-2023 | |
| Amarin Pharma, INC. | $518.95 | 2019-2022 | |
| Radius Health, INC. | $508.62 | 2019-2024 | Tymlos |
| Aimmune Therapeutics, INC. | $460.79 | 2025 | Zenpep, Vowst |
| Ironwood Pharmaceuticals, INC | $396.90 | 2019-2024 | Linzess |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $396.45 | 2021-2023 | Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $394.28 | 2019 | |
| Allergan, INC. | $367.64 | 2019-2020 | |
| Ascendis Pharma Endocrinology INC | $361.33 | 2025 | Yorvipath |
| Madrigal Pharmaceuticals | $343.89 | 2025 | Rezdiffra |
| Sunovion Pharmaceuticals INC. | $330.01 | 2021-2022 | |
| Ibsa Pharma INC. | $326.72 | 2021-2025 | Tirosint, Licart, Flector |
| Novartis Pharmaceuticals Corporation | $314.96 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $306.32 | 2024-2025 | Zoryve |
| Vivus LLC | $300.68 | 2023-2025 | Pancreaze |
| Sumitomo Pharma America, INC. | $262.54 | 2023-2024 | Gemtesa |
| Corium, LLC | $242.95 | 2022-2023 | Adlarity |
| Novo Nordisk INC | $226.66 | 2023-2024 | Ozempic, Rybelsus |
| Teleflex LLC | $179.31 | 2023 | Urolift |
| Phathom Pharmaceuticals, INC. | $164.62 | 2023-2025 | Voquezna |
| Biogen, INC. | $156.31 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $153.98 | 2025 | Rexulti |
| Insightec,INC | $147.04 | 2025 | Exablate |
| Incyte Corporation | $133.94 | 2021 | |
| Kyowa Kirin, INC. | $121.83 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.24 | 2019 | |
| Genentech USA, INC. | $116.62 | 2019-2022 | |
| Urovant Sciences INC | $114.07 | 2022 | |
| Astellas Pharma US INC | $59.63 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $54.21 | 2020-2021 | |
| Pfizer INC. | $43.44 | 2019-2020 | |
| Exact Sciences Corporation | $39.04 | 2025 | Cologuard Collection Kit |
| Scilex Pharmaceuticals INC. | $36.05 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Weiguo Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.